Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The ACO/ARO/AIO-21 investigator-driven, open-labeled, phase I drug re-purposing trial will
assess whether the IL-1 receptor antagonist Anakinra can be safely combined with
fluoropyrimidine-based chemoradiotherapy (CRT) in patients with rectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Goethe University
Treatments:
Capecitabine Interleukin 1 Receptor Antagonist Protein